IL6 and neoplasm: Blocking S100A9 interactions with ABR-238901 did not directly affect MDSC accumulation but did reduce IL-6 and IL-10 expression by MDSC. ABR-238901 treatment in combination with bortezomib resulted in an increased reduction in tumor load compared with single treatments.